Novo Nordisk India unveils oral Semaglutide to treat diabetes

Published On 2022-01-25 12:23 GMT   |   Update On 2022-01-25 12:23 GMT

Drug firm Novo Nordisk India on Thursday said it has launched a first of its kind diabetes treatment medication in the country. The company said it has introduced the world's first and only oral semaglutide, a game-changer in diabetes management. Semaglutide, a GLP-1 receptor analogue (GLP-1 RA) - one of the drug classes to treat diabetes, till now was available only in the form of...

Login or Register to read the full article

Drug firm Novo Nordisk India on Thursday said it has launched a first of its kind diabetes treatment medication in the country. The company said it has introduced the world's first and only oral semaglutide, a game-changer in diabetes management.

Semaglutide, a GLP-1 receptor analogue (GLP-1 RA) - one of the drug classes to treat diabetes, till now was available only in the form of injections and this is the first time such medication has been developed in an oral form.

For more information, check out the full story on the link below: 

First: Novo Nordisk India launches oral Semaglutide for diabetes treatment

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News